Additionally, Agdashian et al. [102] noted that tremelimumab treatment can stimulate the activation of tumor-specific T cells, decrease T-cell clonality, and enhance the infiltration of CD3+ CD8+ T cells into the tumor, leading to noteworthy clinical and immunological outcomes in patients with HCC. This evidence concerns the gene CD8A and hepatocellular carcinoma.